Recs
October 20, 2009 – Comments (9) | RELATED TICKERS: EXEL
I'm highly invested in EXEL. I've had a good run with it, but am now losing all my gains. After hours tonight it is still going down. Is there something everyone knows but me? Sure appreciate any input.
Quite frankly, the machine doesn't work very well!
Doctors are reporting very high instances of complications from their machinery.
This does not bode well when the costs are high to buy the machine to begin with and hospitals are struggeling.
I would sell while I still have a gain if I were you.
First off I will give you my opinion of the stock chart of this company.... a sell signal occured In late September,however, the stock has been holding (ON THE CLOSE) above $5.97. Any CLOSE below $5.97 would send me to the exits,at least In the short term. You also have to remember that they will be reporting their earnings on October 29th. The way the stock Is trending It my be an Indication that earnings may miss estimates. Biotech companies trade on NEWS EVENTS for the most part when they are In the developmental stages. The data here Is very encouraging for this particular drug... http://www.exelixis.com/downloads/XL184-201_ASCO-2009_Imaging-Poster-2048.pdf This Is a tough call,depending on how much profit you have,but In my opinion when looking at the company as a whole,they seem to have some very promising drugs In their pipeline,and It would not surprise me to se this stock go higher IN THE LONGER TERM.... I do not really see a BIG downside to this stock,even If their earnings miss a bit. I will be following this little company now,as they seem quite Intriguing LONGER TERM... Step back,and remember why you bought this company In the first place. If you still believe that your reasons were based on solid research,stick with It. I have sold MANY a stock too early,and I have found that patience Is sometimes well rewarded If you stick to your guns.... good luck... TS
#1) On October 20, 2009 at 10:08 PM, ChrisGraley (99.42) wrote:Quite frankly, the machine doesn't work very well! What machine???? {At Exelixis, our vision is to be a world-class commercial biotechnology company.}
We believe that we can achieve this with an approach of focused excellence in everything that we do - in working efficiently, in making data-driven decisions quickly, in advancing promising compounds rapidly and in leveraging our robust pipeline to establish partnerships and licensing agreements with leading biotechnology and pharmaceutical companies. The outcome of that strategy to-date is a diverse and quality pipeline of 14 compounds focused on oncology.
Our compounds target multiple receptor tyrosine kinases simultaneously, as well as components of key components of downstream signaling pathways that play important roles in cancer and metabolic diseases. With world-class discovery capabilities, we have an engine to drive continued replenishment of our clinical pipeline, creating a flow of ongoing opportunities for creating value in the clinic and the marketplace.
We take a pragmatic approach to product development, internally developing programs with clear and relatively short paths to market and working with partners to develop those programs with more costly or complex development trajectories. Our current focus is on undertaking a vigorous and expansive clinical development program for our lead compound XL184 with our partner, Bristol-Myers Squibb Company, while making strategic investments in earlier pipeline programs with an eye toward reaching “go/no-go” decisions as efficiently as possible. As these earlier programs progress, we intend to maintain our strategy of balancing internal and collaborative development programs with out-licensing transactions.
Aware that many of today's patients with cancer and other serious diseases have significant unmet medical needs, we are driven by a sense of urgency that mandates that we think large and move fast, pursuing a better way to better medicine. http://www.exelixis.com/
Another positive for the company Is the 35 job openings currently listed on their site. They are obviously gearing up for a transition to marketing and production In the not too distant future. The company Is not lacking In confidence....... TS
it's those inconsiderate profit taking baastahds - just like always....
Buyers 64
6,276,302 shares
Sellers 107
21,415,436 shares
Great responses all. Thanks, lots to digest.
Sorry Janice I was thinking of the wrong stock.
Nothing really going on with EXEL that I know of other than that they are about to report earnings. Could be a few people trading on inside info.
Take a look at Lexicon Pharmaceuticals,and Ariad Pharmaceuticals If you want some bang for your buck. The downside risk on these two Is minimal at this time especially Lexicn.... Lexicon @ $1.55 Ariad @ $2.07 (LXRX) (ARIA) http://www.lexicon-genetics.com/ http://www.ariad.com/ TS
Traders may indeed be pushing this stock down on expected earnings, but what do earnings have to do with a company which derives ALL it's current revenue from partner payments. Considering how much those partners have already ponied up for the most promising compounds, I would be a long term holder (which I am). If this stock goes down into friday I will be adding to my 3000 shares.
View More
Terms & Conditions
RSS Headlines
Fool UK